(Q53036812)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Eitan Amir

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Mairéad Mcnamara

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

9

Ian F Tannock

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1

Arnoud J Templeton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Francisco Vera-Badillo

6

object named as

Francisco E Vera-Badillo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

5

Raya Leibowitz-Amit

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Carmel Pezaro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Aurelius Omlin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Johann S de Bono

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

3 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

3346-3352

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature

21 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

REporting recommendations for tumour MARKer prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Neutrophil to lymphocyte ratio and cardiovascular diseases: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Alpha emitter radium-223 and survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

inferred from DOI database lookup

7 January 2021

based on heuristic

Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

inferred from DOI database lookup

7 January 2021

based on heuristic

Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28890

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.28890

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24995769%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference